Treatment of testicular germ-cell cancer: A cochrane evidence-based systematic review

Cancer Treatment Reviews

Volumn 28, Issue 5, 2002, Pages 237-253

  Shelley, M D ^a   Mason, M D ^a  

^a Velindre NHS Trust   (United Kingdom)

Author keywords

Evidence based medicine; Testicular germ cell cancer; Treatment

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FILGRASTRIM; IFOSFAMIDE; METOCLOPRAMIDE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; TROPISETRON; VINBLASTINE; VINCRISTINE;

ALOPECIA; BONE MARROW TOXICITY; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LYMPH NODE IRRADIATION; NAUSEA AND VOMITING; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OTOTOXICITY; PROGNOSIS; REPRODUCTIVE TOXICITY; REVIEW; SEMINOMA; TESTIS CANCER; THROMBOCYTOPENIA;

EID: 0036815834     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00059-2     Document Type: Article

References (66)

1. Adami HO, Bergstrom R, Mohner M, et al. Testicular cancer in nine northern European countries. Int J Cancer 1994; 59(1): 33-38.
2. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary?. J Urol 1995; 153(3 Pt 2): 981-985.
3. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a medical research council randomized trial. J Clin Oncol 1999; 17(4): 1146-1154.
4. Jones WG, Fosså SD, Mead GM, et al. Preliminary results of a international randomised trial of radiotherapy at two dose schedules of 20Gy versus 30Gy (at 2Gy/day) as adjuvant treatment of stage 1 seminoma testis, including morbidity and quality of life data (MRC study TE18). In: Fifth International Germ Cell Tumour Conference. University of Leeds: Leeds, 2001.
5. Fossa S, Jones WG, Stenning SP. for the TE18 Collaborators, MRC Clinical Trials Unit, London, UK Quality of life (QL) after radiotherapy (RT) for stage I seminoma: results from a randomised trial of two RT schedules (MRC TE18). Proc Ann Meet Am Soc Clin Oncol 2002; 750.
6. Aass N, Hatun DE, Thoresen M, Fosså SD. Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol 1997; 45: 125-128.
7. Khoo VS, Rainford K, Horwich A, Dearnaley DP. The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomised pilot study. Clin Oncol 1997; 9(4): 252-257.
8. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993; 29A(14): 1931-1934.
9. Warde PR, Gospodarowicz MK, Goodman PJ, et al. Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1993; 27(1): 11-15.
10. Peckham MJ, Hamilton CR, Horwich A, Hendry WF. Surveillance after orchiectomy for stage I seminoma of the testis. Br J Urol 1987; 59(4): 343-347.
11. Duchesne GM, Horwich A, Dearnaley DP, et al. Orchidectomy alone for stage I seminoma of the testis. Cancer 1990; 65(5): 1115-1118.
12. Warde P, von de Maase H, Horwich A, Gospodarowicz M, Panzarella T, Specht L. Prognostic factors for relapse in stage I seminoma managed by surveillance. Proc Ann Meet Am Soc Clin Oncol 1998; 1188.
13. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 1992; 65(5): 775-778.
14. Bokemeyer C, Schmoll HJ. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995; 13(1): 283-292.
15. Oliver RT, Edmonds PM, Ong JY, et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy. Int J Radiat Oncol Biol Phys 1994; 290(1): 3-8.
16. Dieckmann KP, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient?. Urology 2000; 55(1): 102-106.
17. Read G, Stenning S. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research council testicular tumours working party. J Clin Oncol 1992; 10: 1762-1768.
18. Rorth M, Jacobsen GK, Von der Maase H, et al. Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. J Clin Oncol 1991; 9(9): 1543-1548.
19. Dearnaley DP, Stenning SP. Management of clinical stage1 nonseminomatous germ cell tumours (NSGCT): influence of prognostic factors on choice of treatment. In: Jones WG, Appleyard I, Harnden P (eds.), Germ Cell Tumours IV. John Libbey: London, 1998; 187-188.
20. Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage-II testicular cancer. N Engl J Med 1987; 317(23): 1433-1438.
21. Weissbach L, Hartlapp JH. Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 1991; 146(5): 1295-1298.
22. Cullen MH, Billingham LJ, Cook J, Woodroffe CM. Management preferences in stage I non-seminomatous germ cell tumours of the testis: an investigation among patients, controls and oncologists. Br J Cancer 1996; 74(9): 1487-1491.
23. Dearnaley DP, Fosså SD, Kaye SB, et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high risk clinical stage I (HRCSI) non-seminomatous germ cell tumours (NSGCT) - a Medical Research Council (MRC) pilot study. Proc Ann Meet Am Soc Clin Oncol 1998; 1189.
24. Koocher G, O'Malley J. The Damocles Syndrome: Psychosocial Consequences of Surviving Childhood Cancer. McGraw-Hill: New York, 1981.
25. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification; a prognostic factor based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15(2): 594-603.
26. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316(23): 1435-1440.
27. Dearnaley DP, Horwich A, A'Hern R, et al. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer 1991; 27(6): 684-691.
28. Horwich A, Sleijfer DT, Fosså SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15(5): 1844-1852.
29. Bokemeyer C, Kohrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7(10): 1015-1021.
30. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11(4): 598-606.
31. Horwich A, Oliver RTD, Wilkinson PM, et al. A Medical Research Council randomised trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer 2000; 83(12): 1623-1629.
32. Clemm C, Bokemeyer C, Gerl A, et al. Randomised trial comparing cisplatin/etoposide/ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma. Proc Ann Meet Am Soc Clin Oncol 2000: 1293.
33. Levi JA, Raghavan D, Harvey V, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 1993; 11(7): 1300-1305.
34. Loehrer Sr. PJ, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13(2): 470-476.
35. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomised study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15(5): 1837-1843.
36. Culine P, Kerbrat J, Bouzy C, et al. Are 3 cycles of bleomycin, etoposide and cisplatin (3BEP) or4 cycles of etoposide and cisplatin (4EP) equivalent regimenns for patients (pts) with good-risk metastatic nonseminomatous germ cell tumors (NSGCT)? Preliminary results of a randomised trial. Proc Ann Meet Am Soc Clin Oncol 1999; 1: 1188.
37. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide+cisplatin versus vinblastine+bleomycin+ cisplatin+cyclophosphamide+dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988; 6(8): 1231-1238.
38. de Wit R, Stoter G, Sleijfer D, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular nonseminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1998; 78(6): 828-832.
39. Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981; 305(13): 727-731.
40. Levi JA, Thomson D, Sandeman T, et al. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. J Clin Oncol 1988; 6(7): 1154-1160.
41. Stoter G, Sleyfer DT, Tenbokkelhuinink WW, et al. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of nonseminotamous testicular cancer - a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1986; 4(8): 1199-1206.
42. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7(3): 387-391.
43. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomised study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research. J Clin Oncol 2001; 19(6): 1629-1640.
44. Toner G, Stockler M. Comparison of two standard chemotherapy regimenns for good prognosis germ cell tumours; a randomised trial. Lancet 2001; 357: 739-745.
45. Stockler M, Toner GC, Lewis C, et al. Health-related quality of life (HRQL) in a randomised trial of two standard chemotherapy regimens for good-prognosis germ cell tumours: the ANZ germ cell trials group good prognosis trial. Proc Ann Meet Am Soc Clin Oncol 2002; 743.
46. Fizazi KDK-A, Wang X, Finn L, Logothetis CJ, Amato RJ. A 20% reduction of the original CIS/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ cell tumors: final results of a phase III randomised trial. Ann Oncol 2002; 13: 125-134.
47. DeWys WD, Begg C, Slayton R, Hahn RG, Brodsky I. Chemotherapy for advanced germinal cell neoplasms: preliminary report of an Eastern Cooperative Oncology Group Study. Cancer Treat Rep 1979; 63(9-10): 1675-1680.
48. Nichols CR, Williams SD, Loehrer PJ, et al. Randomised study of cisplatin dose intensity in poor-risk germ-cell tumors - a Southeastern-Cancer-Study-Group and Southwest-Oncology-Group Protocol. J Clin Oncol 1991; 9(7): 1163-1172.
49. Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone-marrow transplantation in 1st line treatment of poor risk nonseminomatous germ-cell tumors - preliminary results of a french randomised trial. Eur Urol 1993; 23(1): 213-218.
50. Rosti G, Pico J-L, Wandt H, et al. High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94. Proc Ann Meet Am Soc Clin Oncol 2002; 716.
51. Samson MK, Rivkin SE, Jones SE, et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer - a Southwest Oncology Group Study. Cancer 1984; 53(5): 1029-1035.
52. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomised trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988; 6(6): 1031-1040.
53. Bokemeyer C, Harstrick A, Beyer J, et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol 1998; 25(2 Suppl 4):24-32.
54. Beyer J. High dose versus conventional dose first salvage treatment in nonseminoma; a matched pair analysis. Proc Ann Meet Am Soc Clin Oncol 1999; 1255.
55. de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus an alternating regimen of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995; 71(6): 1311-1314.
56. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced-disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 1998; 16(4): 1287-1293.
57. Droz J-P, Culine S, Bouzy J, et al. Preliminary results of a randomised trial comparing bleomycin, etoposide, cisplatin (BEP) and cyclophosphamide, doxorubicin, cisplatin/vinblastin, bleomycin (CISCA/VB) for patients (Pts) with intermediate- and poor-risk metastatic nonseminomatous germ-cell tumors (NSGCT). Proc Ann Meet Am Soc Clin Oncol 2001; 690.
58. Kaye SB, Mead GM, Fosså S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomised Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998; 16(2): 692-701.
59. Fosså SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16(2): 716-724.
60. Wozniak AJ, Samson MK, Shah NT, et al. A randomised trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 1991; 9(1): 70-76.
61. Horwich A, Mason M, Fosså SD, et al. Accelerated induction chemotherapy (C-BOP-BEP) for poor and intermediate prognosis metastatic germ cell tumours (GCT). Proc Ann Meet Am Soc Clin Oncol 1997: 1137.
62. Javadpour N, Ozols RF, Anderson T, et al. A randomised trial of cytoreductive surgery followed by chemotherapy versus chemotherapy alone in bulky stage III testicular cancer with poor prognostic features. Cancer 1982; 50(10): 2004-2010.
63. Nazareth ILJ, King M. Sexual function after treatment for testicular cancer: a systematic review. J Psychosomatic Res 2001; 51: 735-743.
64. Jonker-Pool G, Van de Wiel HB, Hoekstra HJ. Sexual functioning after treatment for testicular cancer-review and meta-analysis of 36 empirical studies between 1975 and 2000. Arch Sex Behav 2001; 30(1): 55-74.
65. Fosså S, Aass N, Winderen M, Bõrmer O. Long-term reduction of renal function (RF) in patients (Pts) with testicular cancer (TC). Proc Ann Meet Am Soc Clin Oncol 2001; 771.
66. Moynihan C, Bliss JM, Davidson J, Burchell L, Horwich A. Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial. Br Med J 1998; 316(7129): 429-435.